BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. (BTAI): 8 pipeline candidates · 1 upcoming catalyst · ~6 mo cash runway · 9 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
5.6 months
D/E -1.32 · 0% dilution
Lead: Phase 3
8 candidates
1 upcoming, next in ~149d
0 buys · 4 sells (180d)
A transparent, data-derived signal for BioXcel Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$35.8M
Cash
$17.2M
Quarterly Burn
$11.8M
Runway
5.6 mo
Revenue
$206K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (8 candidates)
| Drug | Phase |
|---|---|
| bxcl501 | Phase 3 |
| BXCL501 (IGALMI® for approved indications) | Phase 3 |
| bxcl501 120 micrograms | Phase 2 |
| bxcl501 60 micrograms | Phase 2 |
| bxcl501 80 micrograms | Phase 2 |
| bxcl501 sublingual film | Phase 3 |
| BXCL701 | Phase 2 |
| bxcl701 monotherapy | Phase 2 |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
39
Total value held
$8.3M
| Holder | Shares | Value |
|---|---|---|
| millennium management llc | 1,936,760 | $2.6M |
| armistice capital, llc | 1,910,076 | $2.6M |
| oaktree capital management lp | 723,564 | $970K |
| vanguard capital management llc | 414,678 | $556K |
| geode capital management, llc | 230,168 | $309K |
| jones financial companies lllp | 131,789 | $166K |
| man group plc | 96,473 | $129K |
| state street corp | 92,118 | $123K |
| fmr llc | 90,300 | $121K |
| oaktree fund advisors, llc | 85,826 | $115K |
Showing top 10 of 39 institutional holders of BioXcel Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in BioXcel Therapeutics, Inc.'s pipeline?
BioXcel Therapeutics, Inc. (BTAI) has 8 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is BioXcel Therapeutics, Inc.'s lead drug candidate?
BioXcel Therapeutics, Inc.'s most advanced tracked candidate is bxcl501 (Phase 3) for Agitation.
What is BioXcel Therapeutics, Inc.'s next catalyst?
BioXcel Therapeutics, Inc.'s next tracked catalyst is a PDUFA event — "PDUFA Date: igalmi" — expected November 14, 2026.
What is BioXcel Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, BioXcel Therapeutics, Inc. has approximately 5.6 months of cash runway.
What is BioXcel Therapeutics, Inc.'s market capitalization?
BioXcel Therapeutics, Inc.'s market capitalization is approximately $35.8M.
Get the full picture on BioXcel Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.